IgA肾病 中国就医指南

IgA nephropathy (IgAN), also known as Berger’s disease, is a chronic autoimmune kidney disorder characterized by the deposition of immunoglobulin A (IgA) immune complexes in the glomerular mesangium. This triggers localized inflammation, mesangial cell proliferation, and extracellular matrix expansion—ultimately leading to progressive glomerulosclerosis, tubulointerstitial fibrosis, and declining renal function. Pathogenesis involves a multifactorial interplay: aberrant glycosylation of IgA1 (particularly deficient galactosylation in the hinge region), generation of autoantibodies against these neoepitopes, formation of circulating IgA1-containing immune complexes, impaired hepatic clearance, and subsequent mesangial deposition. Complement activation—especially via the lectin and alternative pathways—amplifies injury, while genetic susceptibility (e.g., variants in CFHR1, DEFA, HLA-DQB1) and environmental triggers (mucosal infections, gut dysbiosis, smoking) modulate disease onset and progression. Epidemiologically, IgAN is the most common primary glomerulonephritis worldwide, with highest prevalence in East Asia (incidence ~2.5–4.5 per 100,000/year), intermediate rates in Europe (~1.0–2.0), and lower incidence in Africa and Latin America. It typically presents in adolescence or early adulthood (peak onset 16–35 years), with a male-to-female ratio of ~2:1. Key risk factors include familial clustering (10–15% of cases), Asian or Caucasian ethnicity, recurrent upper respiratory or gastrointestinal infections, celiac disease, HIV, and liver cirrhosis. Clinical manifestations range from asymptomatic microscopic hematuria and mild proteinuria to episodic macroscopic hematuria (often post-infectious), hypertension, nephrotic-range proteinuria (>3.5 g/day), and progressive chronic kidney disease (CKD). Approximately 20–40% of untreated patients progress to end-stage kidney disease (ESKD) within 20 years. Quality of life is significantly impacted—not only by physical symptoms (fatigue, edema, nocturia) but also by psychological burden (anxiety about progression, treatment adherence challenges), dietary restrictions (low-sodium, low-protein diets), medication side effects (e.g., corticosteroid-induced weight gain, mood changes), and socioeconomic strain from long-term monitoring, dialysis, or transplant preparation. Early diagnosis via renal biopsy remains essential for risk stratification, as clinical presentation alone cannot reliably predict prognosis. Emerging biomarkers—including serum galactose-deficient IgA1, anti-glycan antibodies, and urinary CD89 complexes—are under validation for non-invasive monitoring. With growing understanding of pathogenic mechanisms, targeted therapies (e.g., Nefecon, budesonide targeting gut-associated lymphoid tissue; anti-APRIL agents like atacicept and telitacicept) are reshaping management paradigms beyond conventional supportive care.

# IgA肾病治疗方案与费用明细（肾内科）

一、保守治疗（一线基础方案）

适用人群：eGFR ≥60 mL/min/1.73m²、尿蛋白<1g/d、无高血压或控制良好者

• •药物治疗：ACEI/ARB（如缬沙坦，月均200–500元）＋低盐低蛋白饮食管理（营养科随访，单次150元）
• •检验监测：尿常规+尿微量白蛋白/肌酐比（80元/次）、血肌酐+eGFR+IgA水平（120元/次）、24h尿蛋白定量（180元/次），每3个月1次

二、免疫抑制治疗（中高危患者）

适用人群：尿蛋白≥1g/d且eGFR下降趋势，或病理证实系膜增生伴新月体

• •标准方案：糖皮质激素（泼尼松起始0.8mg/kg/d，疗程6个月）＋霉酚酸酯（国产500–900元/月；进口1200–2000元/月）
• •配套检查：肾穿刺活检（含病理+免疫荧光，4800–6200元）、骨密度+血糖血脂（320元）

三、介入/专科治疗（难治性进展期）

适用人群：eGFR 30–59 mL/min/1.73m²、持续大量蛋白尿（>3g/d）、对激素抵抗

• •核心方案：利妥昔单抗（375mg/m²，静脉输注×4次，总费用约18,000–25,000元）＋血浆置换（单次2800元，通常5–7次）

四、终末期替代治疗（eGFR <15 mL/min/1.73m²）

• •血液透析（医保报销后自付约300–600元/次，年均3–5万元）
• •肾移植（术前评估费8000–12,000元；手术+住院总费用25–35万元，含供体匹配及术后首年免疫抑制剂）

方案快速选择指南

✅ 预算有限/早期患者：首选ACEI/ARB+生活方式干预（年均支出≤6000元） ✅ 中高危/蛋白尿显著者：激素+霉酚酸酯（年均自付2–4万元，医保覆盖50–70%） ✅ 耐药/快速进展者：利妥昔单抗联合血浆置换（首年投入约3–5万元） ✅ 终末期患者：优先评估透析适应证，符合条件者启动肾移植评估